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Abstract 
Dense deposit disease (DDD), also known as membranoproliferative glomerulonephritis type 
II, is a rare kidney disorder that is associated with dysregulation of the alternative pathway of 
complement. Autoantibodies against the C3bBb convertase termed C3 nephritic factor are 
common in DDD patients. Here we report an autoantibody that binds to complement factor B 
in a DDD patient who was negative for C3 nephritic factor. This anti-factor B autoantibody 
recognized an epitope within the Bb fragment and was able to bind to the C3bBb convertase. 
Upon binding, the anti-factor B autoantibody stabilized the convertase against both intrinsic 
and factor H-mediated extrinsic decay, and thus enhanced C3 consumption. Functional 
analyses demonstrated that, in contrast to C3 nephritic factor, the anti-factor B autoantibody 
inhibited complement-mediated lysis in vitro due to inhibition of the C5 convertase and the 
terminal complement pathway. Analysis of C5a plasma levels indicated that not all C5 
convertases are inhibited by the autoantibodies in the patient in vivo. Antigen array 
experiments confirmed the presence of anti-factor B autoantibodies and also revealed 
complement activating anti-C1q antibodies in the patient’s plasma. In summary, the present 
report describes a new autoantibody in DDD that binds to factor B and to the alternative 
pathway C3 convertase and alters the kinetics of complement activation and regulation. 
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1. Introduction 
Dense deposit disease (DDD), also termed membranoproliferative glomerulonephritis type II 
(MPGN II), is a rare renal disorder that may present with hematuria, proteinuria, acute 
nephritic syndrome or nephrotic syndrome, and leads to end-stage renal disease in most of the 
affected individuals (Appel et al., 2005). Kidney biopsies show capillary wall thickening, 
mesangial cell proliferation and expansion of the mesangial matrix. Immunofluorescence 
microscopy shows staining for complement C3 usually in the absence of immunoglobulins 
(Smith et al., 2007). The diagnostic hallmark of DDD is the deposition of electron-dense 
material in the glomerular basement membrane. DDD is often accompanied by 
hypocomplementemia, which is indicative of the role of the alternative complement pathway 
in the pathogenesis of DDD (Benz and Amann, 2009). 
The complement system, which consists of ~35 proteins, is a rapidly activated protein 
cascade that plays an important role in host defense against infections and in inflammatory 
processes (Walport 2001; Markiewski and Lambris, 2007). Complement can be activated via 
three major pathways, of which the alternative pathway shows a continuous low-level 
activation in plasma. Spontaneous hydrolysis of the C3 internal thioester bond results in 
C3(H2O), which is able to bind factor B (Pangburn et al., 1981). After cleavage of factor B by 
factor D, C3(H2O)Bb forms the short-lived initial fluid-phase C3 convertase enzyme, which 
cleaves C3 into the anaphylatoxin C3a and the opsonin C3b that covalently binds to target 
surfaces and initiates the formation of the C3bBb convertase. This leads to further C3 
cleavage, C3b production and the generation of more C3bBb. In order to limit convertase 
activity to target surfaces (e.g. microbes), the convertase is regulated in the host by serum 
proteins such as factor H and factor I, and also by membrane-bound regulators. Mutations in 
complement genes have been linked to MPGN (Licht and Fremeaux-Bacchi, 2009). In 
particular, quantitative or functional factor H deficiency, due to mutations in the CFH gene or 
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autoantibody against the regulatory domains of factor H, lead to MPGN (Ault et al.,1997; 
Dragon-Durey et al., 2004; Licht et al., 2006; Pickering et al., 2002; Meri et al., 1992). 
Two forms of autoimmune DDD are known and in both cases autoantibodies affect 
complement regulation. An anti-factor H miniantibody consisting of lambda light-chains, 
which inhibited factor H complement regulatory activity, was identified in a DDD patient 
(Meri et al., 1992; Jokiranta et al., 1999). C3 nephritic factor (C3NeF), an antibody against the 
C3bBb convertase (Spitzer et al., 1969), is found in 50-80% of DDD patients (Schwertz et al., 
2001; Appel et al., 2005). C3NeF binds to a neoepitope on the newly assembled C3bBb, 
increases the half-life of the convertase against both intrinsic and extrinsic, factor H-mediated, 
decay and thus enhances C3 consumption (Daha et al., 1976). However, C3NeF is also found 
in patients with partial lipodystrophy and even in healthy individuals; therefore, its pathogenic 
role is unclear (Appel et al., 2005; Mathieson et al., 1993). In addition, C3NeF is usually 
identified by hemolysis assays (Rother, 1982) or by C3 breakdown products (Davies and 
Norsworthy, 2000), but not by measuring autoantibody binding to the C3 convertase directly, 
which brings uncertainty into the interpretation of literature data. 
In the present study, we identify and characterize a novel autoantibody in DDD against 
factor B in a C3NeF-negative patient. The nature and functional effects of this anti-factor B 
autoantibody are in part distinct from that of C3NeF, because it binds to native factor B, binds 
to and stabilizes the C3 convertase, but inhibits the terminal pathway. 
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2. Methods 
These studies have been approved by the Research Ethics Committee of the Medical Faculty 
of Friedrich Schiller University, and were performed in accordance with the Declaration of 
Helsinki. 
 
2.1. Microtiter plate assays 
Autoantibodies were analyzed by ELISA as described (Józsi et al., 2007), using factor B, 
factor H, factor I, C3 and C3b (Merck Biosciences, Schwalbach, Germany) immobilized at 5 
µg/ml. IgG subtypes were identified using anti-IgG1-IgG4 mAbs or mAbs against lambda and 
kappa light chains (Sigma-Aldrich, Taufkirchen, Germany). For inhibition experiments, the 
patient’s plasma was incubated with factor B or C3 before adding to factor B-coated wells or 
the immobilized factor B was preincubated with factor B- and factor H-specific goat antibody 
(Merck Biosciences) and anti-Ba or anti-Bb mAbs (Quidel; TECOMedical GmbH, Bünde, 
Germany) before the patient’s plasma was added to the wells. IgG was isolated using Protein 
G columns (GE Healthcare, Freiburg, Germany). To remove IgG, plasma samples were 
incubated with Protein G-agarose beads (Sigma-Aldrich) for 30 min at 20°C. Factor B level in 
plasma was measured by ELISA using anti-Bb mAb as catch antibody and polyclonal anti-
factor B as detection antibody. C5a and soluble C5b-9 (sC5b-9) levels in plasma samples 
were measured by ELISA (Quidel). 
 
2.2. Solid-phase C3 convertase assays 
The C3bBb C3 convertase was generated on MaxiSorp microtiter plates (Nunc, Wiesbaden, 
Germany) as described (Hourcade et al., 2002), in DPBS containing 0.1% Tween-20, 4% 
BSA and 2 mM NiCl2. C3b was immobilized at 5 µg/ml at 4°C overnight. After washing, 1 
µg/ml factor B was added together with 250 ng/ml factor D and 500 ng/ml properdin (Merck 
Biosciences) for 2 hr at 37°C in 50 µl. A goat anti-human factor B antibody was used to detect 
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C3bBb. Binding of patient-derived IgG to C3bBb was measured by HRP-conjugated anti-
human IgG (Sigma-Aldrich). For testing the activity of the convertase, 10 µg/ml C3 was 
added for 60 min at 37°C, and generated C3a was measured by ELISA (Quidel). Convertase 
decay in the absence or presence of 1 µg/ml factor H and 500 µg/ml IgG preparations was 
measured by detecting the remaining intact convertase using anti-factor B.  
 
2.3. Hemolysis assays 
5×106 rabbit erythrocytes (BioTrend Chemikalien, Cologne, Germany) were incubated with 
10% normal human plasma, in a final volume of 100 µl, diluted in HEPES-buffer (20 mM 
HEPES, 7 mM MgCl2, 10 mM EGTA, 144 mM NaCl, 1% BSA, pH 7.4). Purified IgG was 
added in DPBS. After 30 min incubation at 37°C, absorbance of the supernatants was 
measured at 414 nm. C3a and C5a levels in the supernatants were measured by ELISA 
(Quidel). 
 
2.4. Generation and analysis of antigen array data 
Antigens were spotted onto nitrocellulose-covered FAST-slides (Whatman, Kent, UK) using 
BioOdyssey Calligrapher miniarrayer (BioRad, CA) then stored at 4°C in sealed bags. Dried 
arrays were rinsed in PBS for 15 min before use then incubated with 20% serum at 37°C for 1 
hr providing suitable conditions for complement activation. Sera were diluted in veronal 
buffer supplemented with 5% BSA, 0.05% Tween 20, Ca2+ and Mg2+. Slides were washed 
with PBS containing 0.05% Tween 20, and first incubated with goat anti-human IgG F(ab’)2-
biotin then, following washing, with a mixture of Alexa647-conjugated goat F(ab’)2 of anti-
human C3 (MP Biomedicals), FITC-conjugated rabbit anti-human C1q (Dako), and PE-
Cy5.5-conjugated streptavidin (eBioscience). Labelling with antibodies was carried out at 
room temperature for 30 min in PBS containing 5% BSA and 0.05% Tween 20. After 
washing, arrays were dried and scanned on Typhoon Trio+ imager (Amersham Bioscience, 
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München, Germany). Images were analyzed with GenePix Pro 6.0 (Molecular Devices, Corp.) 
software. Intensity of fluorescence (FI= FImedian (pixels of spot) –FI median (pixels of local background)) was 
calculated for each spot; the mean of the replicates were used for further analysis. For 
interassay comparisons, C1q, C3 and IgG signals were normalized to printed C1q, Protein G, 
and human IgG spots, respectively. 
 
2.5. Analysis of anti-C1q autoantibodies 
C1q in the IgG preparations was detected by measuring anti-C1q antibody (Merck 
Biosciences) binding to the immobilized IgG fractions (20 µg/ml). IgG binding from plasma 
samples (1:50) to immobilized C1q (2 µg/ml) was measured by ELISA as described (Siegert 
et al., 1990). Samples were diluted in buffer containing 1 M NaCl to exclude interaction of 
C1q globular heads with IgG Fc parts. 
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3. Results 
 
3.1. Patient description 
The patient, an 11-year-old girl, was diagnosed with DDD at the age of 6.3 years, four years 
after a postinfectious period of macrohematuria and proteinuria. She was treated with plasma 
exchanges and fresh frozen plasma, but renal function impaired and dialysis was necessary. 
Nevertheless, proteinuria and low C3 levels were further observed. Complement analysis 
showed reduced C3 level (0.21 mg/ml; normal range: 0.78-2.1 mg/ml) and increased C3d 
(726 mU/l; normal: <40 mU/l) amount in plasma. APH50 was 89% whereas the CH50 was 
32%. The patient was tested negative for C3NeF by a hemolytic assay (Rother, 1982). 
Western blot analyses of plasma samples showed the presence of the complement activation 
fragments C3d and Ba. Factor B levels were 119 µg/ml and 66 µg/ml in two different samples 
(181 µg/ml in pooled normal human plasma; normal range: 75-280 µg/ml). There was no 
known family history of the disease. Genetic analysis of complement genes was not 
performed. 
 
3.2. Identification and characterization of an anti-factor B autoantibody 
Because of signs of complement dysregulation, we have analyzed if autoantibodies distinct 
from C3NeF were present in the patient’s plasma. Factor B, C3, C3b, factor I and factor H 
were immobilized on microtiter plate wells and the presence of IgG autoantibodies was tested 
as described before (Józsi et al., 2007). Anti-factor B IgG was detected only in the patient’s 
plasma but not in four samples from DDD patients with C3NeF and in samples from 10 
healthy controls (Fig. 1a, and data not shown). C3NeF binds to a neoepitope on the C3 
convertase but not to its individual components (Daha and Van Es, 1981). In agreement with 
this, we found no IgG binding from four analyzed C3NeF-positive plasma samples to factor 
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B, C3 or C3b. Thus, the autoantibody of this patient specifically interacts with factor B and is 
distinct from C3NeF. 
The autoantibody showed dose-dependent binding to immobilized factor B from 
plasma (Fig. 1b), and the removal of the plasma IgG fraction abrogated factor B binding (Fig. 
1c). IgG isolated from the patient’s plasma bound to factor B in a dose-dependent manner 
(Fig. 1d). In addition, factor B:IgG complexes in plasma were detected using an anti-factor B 
antibody to catch the complexes (Fig. 1e). IgG-subtype analysis revealed IgG3 anti-factor B 
antibodies with kappa light chains (data not shown). 
To confirm the specificity of the autoantibody, two types of blocking experiments 
were performed. The addition of purified factor B, but not of C3, as competitor soluble 
antigen to the patient’s plasma inhibited autoantibody binding (Fig. 2a). Likewise, polyclonal 
antibodies against factor B inhibited autoantibody reactivity with factor B, but a polyclonal 
anti-factor H antibody, used as a control, failed to block binding (Fig. 2b).  
 
3.3. Localization of the autoantibody binding site on factor B  
In order to determine the binding site of the autoantibody, immobilized factor B was 
preincubated with monoclonal antibodies (mAbs) against the factor B fragments Ba and Bb 
before adding plasma samples to the wells. The anti-Bb mAb inhibited autoantibody binding 
to factor B in a dose-dependent manner, whereas the anti-Ba mAb had no effect, indicating 
that the larger Bb fragment contains the autoantibody binding epitope (Fig. 3). 
 
3.4. The anti-factor B autoantibody binds to and stabilizes the C3 convertase 
Bb is the enzymatically active part of the C3bBb convertase, therefore we have investigated 
whether the anti-factor B autoantibody binds to this enzyme. The solid-phase C3 convertase 
was built up by adding factor B in the presence of factor D and properdin to C3b-coated wells 
(Fig. 4a). To confirm the formation of an active convertase, C3 was added to the wells and C3 
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cleavage was analyzed by measuring the generated C3a fragment by ELISA (Fig. 4a, right 
panel). IgG isolated from the patient’s plasma that contained the anti-factor B antibodies 
bound to the C3-convertase in a dose-dependent manner, similar to IgG derived from a 
C3NeF-positive MPGN patient. By contrast, IgG purified from healthy donors showed no 
binding (Fig. 4b). The anti-factor B autoantibody did not influence the assembly of the 
convertase (data not shown). 
In functional assays, both the intrinsic and the factor H-mediated extrinsic decay of the 
C3bBb convertase were analyzed. The surface-bound C3 convertase was incubated with IgG 
isolated from the patient and from controls in the presence or absence of factor H, and the 
decay was followed for 60 min by measuring bound Bb. The anti-factor B autoantibody 
stabilized the convertase against both spontaneous (Fig. 4c) and factor H-mediated decay 
(Fig. 4d), in a manner similar to C3NeF. IgG isolated from healthy individuals had no 
influence on convertase decay. 
 
3.5. The anti-factor B antibody affects the C5 convertase and the terminal pathway 
Stabilization of the C3 convertase by C3NeF results in enhanced C3 turnover and, 
consequently, in an increased complement activation. To analyze the effect of the anti-factor 
B autoantibody, alternative pathway mediated hemolysis was measured using rabbit red blood 
cells (RRBC). RRBC are lysed in normal human plasma because they lack regulators to 
protect them from human complement-mediated lysis. The anti-factor B autoantibody, when 
added to human plasma, caused a strong inhibition of RRBC lysis in a dose-dependent 
manner, in contrast to the lysis-enhancing effect of C3NeF (Fig. 5a and b). Similar inhibitory 
effect was seen with polyclonal anti-factor B and anti-C3 antibodies. 
The levels of C3a and C5a were analyzed in these samples as a measure of C3- and C5 
convertase activities. Whereas the C3a levels were increased due to the stabilized convertase 
in proportion to the amount of added autoantibody (Fig. 5c), C5a generation was dose-
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dependently inhibited, indicating an inhibitory effect of the anti-factor B autoantibody on the 
C3bBbC3b alternative pathway C5 convertase (Fig. 5d). Thus, although both autoantibodies 
bind to the C3 convertase and enhance C3 consumption, the anti-factor B autoantibody 
inhibits alternative pathway mediated cell lysis, whereas C3NeF enhances the hemolysis. 
 To further analyze the effect of the autoantibody on the terminal pathway in the 
patient, C5a and soluble C5b-9 (sC5b-9) levels were determined in plasma samples. C5a level 
was 16 ng/ml in the initial sample and it was strongly increased (231 ng/ml) in a sample 
collected two years later and containing similarly high amounts of anti-factor B 
autoantibodies. C5a amounts in normal plasma samples, determined in parallel, were below 
10 ng/ml. sC5b-9 levels were slightly higher (0.9-2.2 µg/ml) than in control plasma samples 
(ranging 0.1-1.6 µg/ml). These data indicated that, although patient-derived purified IgG can 
inhibit the terminal pathway in vitro, the autoantibodies in the plasma of the patient do not 
block all C5 convertases and the terminal pathway can still be activated. 
 
3.6. Antigen microarray analysis of autoantibodies 
We set out  to further characterize the autoantibodies of the patient directly from plasma. In 
addition, because IgG3 antibodies are known as a complement activating IgG isotype, we 
wanted to examine the possibility that the anti-factor B autoantibody plays a pathogenic role 
in the patient by activating the classical pathway. A protein microarray was used to 
characterize the functional autoantibody profile of the patient (Papp et al., 2007). In this assay 
antigens are exposed to whole serum, thus this approach better mimics the in vivo situation 
for the formation of antigen-antibody complexes than do purified antibodies in ELISA. IgG 
binding and C3 deposition to a wide array of immobilized antigens from the patient’s plasma 
were determined in parallel. The presence of anti-factor B autoantibodies was confirmed and 
no increased IgG signal was detected at the spots of C3, factor H, factor I and properdin (data 
not shown). Although there was slightly higher C3 deposition on factor B spots from the 
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patient’s plasma compared to normal control, much higher C3 deposition and IgG binding 
were detected on C1q, implying either the presence of complement activating anti-C1q 
antibodies or C3-containing circulating immune complexes (Fig. 6a). These analyses 
indicated no pathologically significant complement activation by the amounts and type of 
anti-factor B autoantibodies present in the patient’s plasma. 
Next, the presence of C1q in the patient’s IgG was analyzed. C1q was present in high 
amounts in the patient’s IgG preparation as compared to IgG from healthy controls, 
suggesting the presence of immune complexes and/or anti-C1q autoantibodies in the patient 
(Fig. 6b). In addition, IgG binding to immobilized C1q was measured in 1 M NaCl to detect 
anti-C1q autoantibodies and to exclude C1q-IgG Fc interactions via the C1q globular heads 
(Siegert et al., 1990). This assay indicated that the patient’s plasma contained autoantibodies 
against the collagen-like region of C1q (Fig. 6c). 
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4. Discussion 
In this report we describe a new anti-factor B autoantibody in DDD that binds to and stabilizes 
the C3 convertase and thus causes enhanced C3 consumption, but in contrast to C3NeF it 
interferes with terminal pathway activation. 
The C3 convertase is central to the amplification of the alternative complement 
pathway by activating several C3 molecules through enzymatic cleavage. C3NeF, an 
autoantibody found in most MPGN patients, increases the half-life of the convertase by 
stabilizing it against decay, thus causing an increased C3 turnover. By changing the balance of 
complement activation and inhibition C3NeF contributes to the disease, in line with the 
involvement of complement dysregulation in DDD (Appel et al., 2005). C3NeF, however, is 
also found in healthy persons and in other pathological conditions, and a clear causative 
relationship for C3NeF and DDD has not been demonstrated (Schwertz et al., 2001; Appel et 
al., 2005; Smith et al., 2007; Spitzer et al., 1990). The appearance of high-affinity C3NeF in 
the patients is possibly antigen-driven, due to neoepitopes exposed on activated complement 
components (Spitzer et al., 1992). 
The anti-factor B autoantibody described here binds to native factor B as well as to the 
Bb fragment that is part of the alternative pathway convertase. Even though the patient was 
negative for an anti-convertase antibody, i.e. C3NeF, in the traditional hemolysis assay used 
to detect C3NeF, an antibody against factor B was identified by ELISA. This autoantibody, 
similar to C3NeF, bound to and stabilized a solid-phase C3bBb convertase and its decay 
inhibitory effect translated into enhanced C3 consumption. However, in contrast to C3NeF, 
the anti-factor B autoantibody reduced C5 turnover in vitro due to a C5 convertase 
(C3bBbC3b) blocking effect (Figs. 4 and 5), probably by preventing the binding of the 
second C3b molecule. This difference is explained by the different binding sites of the two 
types of autoantibodies. The analyzed C3NeF IgGs failed to bind to factor B, C3 and C3b 
(Fig. 1), consistent with C3NeF binding to a neoepitope on C3bBb (Daha and Van Es, 1981). 
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C3NeF likely binds to a neoantigenic site on Bb but it is unable to bind to native factor B 
(Daha and Van Es, 1981). Thus, the two autoantibodies bind to different parts of the 
convertase. 
Previously, two monoclonal antibodies raised against factor B were shown to mimic 
the effects of C3NeF, but a third monoclonal antibody rather facilitated the disassembly of the 
convertase (Daha et al., 1984). Similarly, the various autoantibodies against the C3 convertase 
or its components may differ in their exact binding sites and functional effects. A 
heterogeneity of C3NeF is indeed observed and likely explains the differences in complement 
profiles between DDD patients (Appel et al., 2005; Davis et al., 1977; Daha et al., 1978; 
Mollnes et al., 1986). 
Interpretation of reported C3NeF cases is difficult, due to the apparent heterogeneous 
nature of these autoantibodies, the scarcity of detailed functional studies, and the various 
methods used for C3NeF measurement. A direct detection of autoantibodies is often not 
performed, and the presence of anti-convertase autoantibodies is deduced from hemolysis 
assays. However, an antibody against the C3 convertase that at the same time inhibits the C5 
convertase would be undetected with this method, as shown here (Figs. 1 and 5). In addition, 
the C3 convertase could be stabilized by other means. For instance, gain-of-function 
mutations in factor B and C3 also lead to more stable convertases and higher C3 turnover 
(Goicoechea de Jorge et al., 2007; Roumenina et al., 2009; Frémeaux-Bacchi et al., 2008). 
Our results emphasize the importance of measuring antibodies directly. ELISA assays should 
complement the commonly used hemolysis assay to identify convertase-specific and 
additional anti-complement antibodies. Such solid-phase assay is also suitable to detect the 
antibody-convertase complexes, thus can be used to identify C3NeF (Seino et al., 1987). 
Since in vitro experimental data demonstrated a C3 convertase stabilizing and C5 
convertase inhibitory effect of the purified autoantibodies, we have also analyzed plasma 
samples for signs of terminal pathway activation. These data showed that the terminal 
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pathway can still be activated in the patient’s plasma, thus not all C5 convertases are inhibited 
in vivo by the amounts of anti-factor B autoantibodies present. In addition, because this 
autoantibody affects only the alternative pathway convertases and cannot bind to classical 
pathway convertases, the terminal pathway remains functional. 
Since factor B:IgG complexes were detected in the patient, and the autoantibodies 
were of IgG3 isotype, we investigated the possibility of immune complex-mediated classical 
pathway activation by analyzing the complement activatory capacity of the autoantibodies on 
antigen microarray (Papp et al., 2007). The observed, somewhat elevated C3 deposition on 
factor B spots from the patient’s plasma are unlikely to be of major pathological significance, 
because neither factor B nor IgG are detected in glomerular deposits in DDD (Sethi et al., 
2009). Although the amount of C1q was increased in the IgG fraction of the patient, this 
represented anti-C1q autoantibodies (Fig. 6). In addition, the microarray experiments revealed 
enhanced antibody and C1q binding to nuclear antigens, such as DNA and RNA, indicating 
systemic autoimmune processes (data not shown). Autoantibodies against complement 
components play a critical role in the pathophysiology of several diseases including systemic 
lupus erythematosus, atypical hemolytic uremic syndrome and MPGN (Trouw et al., 2001, 
2003). Anti-C1q autoantibodies in MPGN have been reported before (Strife et al., 1989, 
1990), and such antibodies are usually associated with activation of the classical pathway 
(Frémeaux-Bacchi et al., 1996), which explains the low CH50 value measured in the patient. 
Our data demonstrate that antigen microarrays in combination with complement 
activity testing are a helpful tool to detect various autoantibodies in parallel and to interpret 
their role in autoimmune diseases. Whereas MPGN patients are commonly screened for 
C3NeF, identifying additional antibodies is equally important. In an analogous manner to 
C3NeF, antibodies that bind to the classical pathway convertases, termed C4NeF, may also 
affect complement regulation in the patients (Halbwachs et al., 1980). The presence of such 
additional antibodies may in part explain the differences between patients and the lack of the 
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clear correlation between the presence and amounts of C3NeF and the complement status and 
pathology in DDD patients. 
Due to its stabilizing effect, the anti-factor B autoantibody causes increased C3 
turnover that contributes to the hypocomplementemia and the C3 deposition in the glomeruli 
that is commonly observed in DDD. Analyses of glomerular deposits in DDD showed the 
presence of C3 degradation fragments, C5 and other terminal pathway components (West et 
al., 2001; Sethi et al., 2009), indicating a role for both the alternative and the terminal 
complement pathway. Animal studies comparing factor H-deficient mice and mice deficient 
in both factor H and C5 demonstrated that glomerulonephritis develops in the absence of C5 
and terminal pathway activation, although the latter contribute to glomerular inflammation 
and a more severe pathology (Pickering et al., 2006). Factor B-autoantibody complexes are 
formed on solid-phase C3 convertases but are also present in fluid phase (Fig. 1e). Factor B 
and IgG, however, are not detected in glomerular deposits in DDD (Sethi et al., 2009). This 
suggests that factor B-autoantibody complexes, which could cause some degree of C3 
activation (Fig. 6a), unlikely to be of pathological significance by direct complement 
activation, and that the autoantibodies affect C3 convertase activity outside the glomeruli. 
This is consistent with the established role of impaired fluid phase alternative pathway 
regulation in the pathogenesis of DDD. Thus, the anti-factor B autoantibody likely has a role 
in DDD by altering C3 convertase regulation in plasma, while at the same time not leading to 
C5 consumption. This could be a reason for the normal APH50 level measured in the patient. 
In the present study, it was not possible to systematically analyze samples and 
determine when the autoantibodies appeared in the patient, thus whether they were in a direct 
causative relationship with the disease manifestation. It is more likely that the anti-factor B 
antibody was only one of the factors that contributed to the disease by enhancing C3 turnover. 
In summary, we identify a new autoantibody in DDD that acts on the alternative 
pathway C3 convertase and alters the kinetics of complement activation and regulation. The 
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major differences between the anti-factor B antibody and C3NeF are that (i) the anti-factor B 
antibody is not detected by the hemolysis assay used to identify convertase-specific 
antibodies, (ii) the anti-factor B antibody binds to native factor B as well as to the C3 
convertase, and (iii) the anti-factor B antibody interferes with the C5 convertase. These results 
provide rationale to design studies that address the presence and role of anti-factor B 
autoantibodies in DDD patients and establish their diagnostic and prognostic value. The 
development of new diagnostic tools and a better understanding of the mechanisms of 
complement dysregulation in the patients may lead to specific and effective treatments in the 
future. 
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Figure legends 
Fig. 1. Identification of anti-factor B autoantibodies. 
(a) Binding of IgG autoantibodies from the patient’s plasma and from plasma samples of 
C3NeF-positive patients to the immobilized complement proteins factor B (CFB), C3, C3b, 
factor I (CFI) and factor H (CFH), or to BSA, was analyzed by ELISA. NHP: normal human 
plasma, used as control. Data points show means of duplicate determinations and are 
representative of three experiments. (b) Serial dilutions of the patient’s plasma showed dose-
dependent binding to immobilized factor B in ELISA. (c) Removal of the IgG fraction from 
the patient’s plasma by incubation with Protein G beads resulted in a loss of autoantibody 
binding to factor B. (d) Dose-dependent binding of the IgG fraction, isolated from the 
patient’s plasma, to factor B (auto-CFB IgG). As a control, binding of IgG isolated from 
normal human plasma to factor B is shown. (e) Immune complexes were captured using a 
monoclonal antibody against factor B, and detected with anti-human IgG. Data shown are 
representative of three experiments with similar results. 
 
Fig. 2. Binding specificity of the autoantibody. 
Factor B-specificity was verified in competition experiments. (a) Autoantibody binding from 
the patient’s plasma to immobilized factor B was measured by ELISA in the presence of the 
indicated concentrations of soluble factor B and C3. (b) A polyclonal goat anti-factor B 
antibody dose-dependently inhibited autoantibody binding to immobilized factor B, whereas a 
goat anti-factor H antibody had no effect. Data are representative of three independent 
experiments. 
 
Fig. 3. The autoantibodies bind to the Bb part of factor B. 
Binding of IgG antibodies to immobilized factor B from the patient’s plasma was measured 
after the factor B-coated wells had been preincubated with increasing concentrations of anti-
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Ba and anti-Bb monoclonal antibodies. Data are representative of three independent 
experiments. 
 
Fig. 4. Anti-factor B autoantibodies bind to and stabilize the C3bBb convertase. 
(a) Solid-phase alternative pathway C3 convertase was built up on microtiter plates by 
incubating factor B (B) with factor D (D) on immobilized C3b in the presence of properdin 
(P) as described by Hourcade et al. (2002). The assembly of the convertase was shown by the 
presence of the Bb fragment measured by a polyclonal anti-factor B antibody in ELISA (left 
panel). This convertase was functionally active and could cleave C3. 10 µg/ml C3 was added 
for 60 min, and the amount of the generated C3a was measured by ELISA (right panel). (b) 
IgG isolated from the anti-factor B autoantibody positive patient (auto-CFB IgG) and from 
C3NeF-containing plasma (C3NeF IgG) were tested for C3 convertase binding in comparison 
to control IgG. Convertase decay was followed after addition of 500 µg/ml purified IgG (c) in 
the absence (spontaneous decay) or (d) in the presence of 1 µg/ml factor H (CFH) (factor H-
mediated decay). Data are representative of three independent experiments. 
 
Fig. 5. Anti-factor B autoantibodies inhibit complement-mediated lysis of rabbit 
erythrocytes. 
(a) Rabbit red blood cells were incubated with 10% human plasma without (-) or with the 
addition of 1 mg/ml purified IgG fractions (in PBS) for 30 min at 37°C, and complement-
mediated lysis was measured as hemoglobin release at 414 nm. In a control tube, the same 
volume of PBS was added as a buffer control (labeled ‘PBS’). Polyclonal antibodies against 
factor B and C3 were also used as controls. (b) The lysis inhibitory effect of anti-factor B 
autoantibodies and the lysis enhancing effect of C3NeF were dose-dependent. C3a (c) and 
C5a (d) were measured from the supernatants by ELISA. The effect of C3NeF (1 mg/ml) is 
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shown as a control. Data represent means of duplicates and are representative of three 
independent experiments. 
 
Fig. 6. Analysis of the complement activating capacity of autoantibodies and the 
presence of anti-C1q autoantibodies. 
(a) Antigen microarray was used to measure complement activation by autoantibodies in 
plasma samples. IgG binding and C3 deposition on factor B (circles) and C1q (triangles) from 
control plasma (white symbols) and from the patient’s plasma (black symbols) are shown. 
Note the logarithmic scale of the y-axis. RFU: relative fluorescence units. Data are 
representative of three experiments. (b) Immobilized purified IgG fractions (20 µg/ml) from 
the patient with anti-factor B autoantibody and from a healthy individual were analyzed for 
the presence of C1q by ELISA. (c) IgG binding to immobilized C1q in high-salt (1 M NaCl) 
buffer was measured from plasma samples to detect anti-C1q autoantibodies. NHP: normal 
human plasma. Data are representative of two experiments. 





